RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 Optimized and New Therapies Will Improve Prognosis in Patients with Advanced Prostate Cancer
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 14
SP 24
OP 26
DO 10.1177/155989771414015
UL http://mdc.sagepub.com/content/14/14/24.abstract
AB The androgen receptor (AR) remains the most important target for metastatic castration-resistant prostate cancer (mCRPC). This article discusses new treatment modalities, including androgen synthesis inhibitors, chemotherapy, immunotherapy and radionuclide therapy.